G. Lenz, M.D., G. Wright, Ph.D., S.S. Dave, M.D., W. Xiao, Ph.D., J. Powell, M.S., H. Zhao, M.S., W. Xu, M.S., B. Tan, M.D., N. Goldschmidt, M.D., J. Iqbal, Ph.D., J. Vose, M.D., M. Bast, B.S., K. Fu, M.D., Ph.D., D.D. Weisenburger, M.D., T.C. Greiner, M.D., J.O. Armitage, M.D., A. Kyle, Ph.D., L. May, Ph.D., R.D. Gascoyne, M.D., J.M. Connors, M.D., G. Troen, Ph.D., H. Holte, M.D., Ph.D., S. Kvaloy, M.D., Ph.D., D. Dierickx, M.D., G. Verhoef, M.D., J. Delabie, M.D., E.B. Smeland, M.D., Ph.D., P. Jares, Ph.D., A. Martinez, M.D., A. Lopez-Guillermo, M.D., E. Montserrat, M.D., E. Campo, M.D., R.M. Braziel, M.D., T.P. Miller, M.D., L.M. Rimsza, M.D., J.R. Cook, M.D., B. Pohlman, M.D., J. Sweetenham, M.D., R.R. Tubbs, M.D., R.I. Fisher, M.D., E. Hartmann, M.D., A. Rosenwald, M.D., G. Ott, M.D., H.-K. Muller-Hermelink, M.D., D. Wrench, M.D., T.A. Lister, M.D., E.S. Jaffe, M.D., W.H. Wilson, M.D., Ph.D., W.C. Chan, M.D., L.M. Staudt, M.D., Ph.D., for the Lymphoma/Leukemia Molecular Profiling Project
Background The addition of rituximab to combination chemotherapywith cyclophosphamide, doxorubicin, vincristine, and prednisone(CHOP), or R-CHOP, has significantly improved the survival ofpatients with diffuse large-B-cell lymphoma. Whether gene-expressionsignatures correlate with survival after treatment of diffuselarge-B-cell lymphoma is unclear.
Methods We profiled gene expression in pretreatment biopsy specimensfrom 181 patients with diffuse large-B-cell lymphoma who receivedCHOP and 233 patients with this disease who received R-CHOP.A multivariate gene-expression–based survival-predictormodel derived from a training group was tested in a validationgroup.
Results A multivariate model created from three gene-expressionsignatures — termed "germinal-center B-cell," "stromal-1,"and "stromal-2" — predicted survival both in patientswho received CHOP and patients who received R-CHOP. The prognosticallyfavorable stromal-1 signature reflected extracellular-matrixdeposition and histiocytic infiltration. By contrast, the prognosticallyunfavorable stromal-2 signature reflected tumor blood-vesseldensity.
Conclusions Survival after treatment of diffuse large-B-celllymphoma is influenced by differences in immune cells, fibrosis,and angiogenesis in the tumor microenvironment.
Source Information
The affiliations of the authors are listed in the Appendix.
Address reprint requests to Dr. Staudt at the Metabolism Branch, Center for Cancer Research, National Cancer Institute, Bldg. 10, Rm. 4N114, National Institutes of Health, Bethesda, MD 20892, or at lstaudt{at}mail.nih.gov.
Iqbal, J., Weisenburger, D. D., Greiner, T. C., Vose, J. M., McKeithan, T., Kucuk, C., Geng, H., Deffenbacher, K., Smith, L., Dybkaer, K., Nakamura, S., Seto, M., Delabie, J., Berger, F., Loong, F., Au, W. Y., Ko, Y.-H., Sng, I., Armitage, J. O., Chan, W. C., for the International Peripheral T-Cell Lymphoma P,
(2010). Molecular signatures to improve diagnosis in peripheral T-cell lymphoma and prognostication in angioimmunoblastic T-cell lymphoma. Blood
115: 1026-1036
[Abstract][Full Text]
Shustik, J., Han, G., Farinha, P., Johnson, N. A., Ben Neriah, S., Connors, J. M., Sehn, L. H., Horsman, D. E., Gascoyne, R. D., Steidl, C.
(2010). Correlations between BCL6 rearrangement and outcome in patients with diffuse large B-cell lymphoma treated with CHOP or R-CHOP. haematol
95: 96-101
[Abstract][Full Text]
Hailfinger, S., Lenz, G., Ngo, V., Posvitz-Fejfar, A., Rebeaud, F., Guzzardi, M., Penas, E.-M. M., Dierlamm, J., Chan, W. C., Staudt, L. M., Thome, M.
(2009). Essential role of MALT1 protease activity in activated B cell-like diffuse large B-cell lymphoma. Proc. Natl. Acad. Sci. USA
106: 19946-19951
[Abstract][Full Text]
Copie-Bergman, C., Gaulard, P., Leroy, K., Briere, J., Baia, M., Jais, J.-P., Salles, G. A., Berger, F., Haioun, C., Tilly, H., Emile, J.-F., Banham, A. H., Mounier, N., Gisselbrecht, C., Feugier, P., Coiffier, B., Molina, T. J.
(2009). Immuno-Fluorescence In Situ Hybridization Index Predicts Survival in Patients With Diffuse Large B-Cell Lymphoma Treated With R-CHOP: A GELA Study. JCO
27: 5573-5579
[Abstract][Full Text]
Bernd, H.-W., Ziepert, M., Thorns, C., Klapper, W., Wacker, H.-H., Hummel, M., Stein, H., Hansmann, M.-L., Ott, G., Rosenwald, A., Muller-Hermelink, H.-K., Barth, T. F. E., Moller, P., Cogliatti, S. B., Pfreundschuh, M., Schmitz, N., Trumper, L., Holler, S., Loffler, M., Feller, A. C., for the German High Grade Non-Hodgkin's Lymphoma S,
(2009). Loss of HLA-DR expression and immunoblastic morphology predict adverse outcome in diffuse large B-cell lymphoma - analyses of cases from two prospective randomized clinical trials. haematol
94: 1569-1580
[Abstract][Full Text]
Burger, J. A., Ghia, P., Rosenwald, A., Caligaris-Cappio, F.
(2009). The microenvironment in mature B-cell malignancies: a target for new treatment strategies. Blood
114: 3367-3375
[Abstract][Full Text]
Wilcox, R. A., Wada, D. A., Ziesmer, S. C., Elsawa, S. F., Comfere, N. I., Dietz, A. B., Novak, A. J., Witzig, T. E., Feldman, A. L., Pittelkow, M. R., Ansell, S. M.
(2009). Monocytes promote tumor cell survival in T-cell lymphoproliferative disorders and are impaired in their ability to differentiate into mature dendritic cells. Blood
114: 2936-2944
[Abstract][Full Text]
Dornan, D., Bennett, F., Chen, Y., Dennis, M., Eaton, D., Elkins, K., French, D., Go, M. A. T., Jack, A., Junutula, J. R., Koeppen, H., Lau, J., McBride, J., Rawstron, A., Shi, X., Yu, N., Yu, S.-F., Yue, P., Zheng, B., Ebens, A., Polson, A. G.
(2009). Therapeutic potential of an anti-CD79b antibody-drug conjugate, anti-CD79b-vc-MMAE, for the treatment of non-Hodgkin lymphoma. Blood
114: 2721-2729
[Abstract][Full Text]
Wilcox, R. A., Feldman, A. L., Wada, D. A., Yang, Z.-Z., Comfere, N. I., Dong, H., Kwon, E. D., Novak, A. J., Markovic, S. N., Pittelkow, M. R., Witzig, T. E., Ansell, S. M.
(2009). B7-H1 (PD-L1, CD274) suppresses host immunity in T-cell lymphoproliferative disorders. Blood
114: 2149-2158
[Abstract][Full Text]
Vitolo, U., Chiappella, A., Angelucci, E., Rossi, G., Liberati, A. M., Cabras, M. G., Botto, B., Ciccone, G., Gaidano, G., Falchi, L., Freilone, R., Novero, D., Orsucci, L., Pavone, V., Pogliani, E., Rota-Scalabrini, D., Salvi, F., Tonso, A., Tucci, A., Levis, A., on behalf of Gruppo Italiano Multiregionale Linfom,
(2009). Dose-dense and high-dose chemotherapy plus rituximab with autologous stem cell transplantation for primary treatment of diffuse large B-cell lymphoma with a poor prognosis: a phase II multicenter study. haematol
94: 1250-1258
[Abstract][Full Text]
Choi, W. W.L., Weisenburger, D. D., Greiner, T. C., Piris, M. A., Banham, A. H., Delabie, J., Braziel, R. M., Geng, H., Iqbal, J., Lenz, G., Vose, J. M., Hans, C. P., Fu, K., Smith, L. M., Li, M., Liu, Z., Gascoyne, R. D., Rosenwald, A., Ott, G., Rimsza, L. M., Campo, E., Jaffe, E. S., Jaye, D. L., Staudt, L. M., Chan, W. C.
(2009). A New Immunostain Algorithm Classifies Diffuse Large B-Cell Lymphoma into Molecular Subtypes with High Accuracy. Clin. Cancer Res.
15: 5494-5502
[Abstract][Full Text]
Alizadeh, A. A., Gentles, A. J., Lossos, I. S., Levy, R.
(2009). Molecular Outcome Prediction in Diffuse Large-B-Cell Lymphoma. NEJM
360: 2794-2795
[Full Text]
Li, C., Kim, S.-W., Rai, D., Bolla, A. R., Adhvaryu, S., Kinney, M. C., Robetorye, R. S., Aguiar, R. C. T.
(2009). Copy number abnormalities, MYC activity, and the genetic fingerprint of normal B cells mechanistically define the microRNA profile of diffuse large B-cell lymphoma. Blood
113: 6681-6690
[Abstract][Full Text]
Kim, S.-W., Rai, D., McKeller, M. R., Aguiar, R. C. T.
(2009). Rational combined targeting of phosphodiesterase 4B and SYK in DLBCL. Blood
113: 6153-6160
[Abstract][Full Text]
Dunleavy, K., Pittaluga, S., Czuczman, M. S., Dave, S. S., Wright, G., Grant, N., Shovlin, M., Jaffe, E. S., Janik, J. E., Staudt, L. M., Wilson, W. H.
(2009). Differential efficacy of bortezomib plus chemotherapy within molecular subtypes of diffuse large B-cell lymphoma. Blood
113: 6069-6076
[Abstract][Full Text]
Bacher, U., Kohlmann, A., Haferlach, T.
(2009). Perspectives of gene expression profiling for diagnosis and therapy in haematological malignancies. Brief Funct Genomic Proteomic
0: elp011v1-elp011
[Abstract][Full Text]
Kurtova, A. V., Tamayo, A. T., Ford, R. J., Burger, J. A.
(2009). Mantle cell lymphoma cells express high levels of CXCR4, CXCR5, and VLA-4 (CD49d): importance for interactions with the stromal microenvironment and specific targeting. Blood
113: 4604-4613
[Abstract][Full Text]
Johnson, N. A., Boyle, M., Bashashati, A., Leach, S., Brooks-Wilson, A., Sehn, L. H., Chhanabhai, M., Brinkman, R. R., Connors, J. M., Weng, A. P., Gascoyne, R. D.
(2009). Diffuse large B-cell lymphoma: reduced CD20 expression is associated with an inferior survival. Blood
113: 3773-3780
[Abstract][Full Text]
Jaffe, E. S.
(2009). The 2008 WHO classification of lymphomas: implications for clinical practice and translational research. ASH Education Book
2009: 523-531
[Abstract][Full Text]
Eng, C.
(2008). Microenvironmental Protection in Diffuse Large-B-Cell Lymphoma. NEJM
359: 2379-2381
[Full Text]
(2008). Tumor Microenvironment and Survival in Large B-Cell Lymphoma. JWatch Oncology and Hematology
2008: 1-1
[Full Text]
Previous
